CIK 0001515673
- Large accelerated filer
Ultragenyx Pharmaceutical Inc.
Sign in to watch- Ticker
- RARE
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 272546083
- Phone
- +1 415-483-8800
- Business address
- 60 LEVERONI COURT, NOVATO, CA, 94949
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $127,561
- in 3 filings, $17K under 10b5-1 plans
Net −$127,561. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2020-04-19 | KAKKIS EMIL D President & CEO | Shares withheld for taxes | −851 | $58.57 | $50K | 653,649 |
| 2020-04-19 | Huizenga Theodore Alan SVP, Controller and PAO | Shares withheld for taxes | −140 | $58.57 | $8K | 19,818 |
| 2020-04-19 | Huang Dennis Karl EVP & Chief Tech Ops Officer | Shares withheld for taxes | −248 | $58.57 | $15K | 35,227 |
| 2020-04-19 | Harris Erik EVP & Chief Commercial Officer | Shares withheld for taxes | −210 | $58.57 | $12K | 24,362 |
| 2020-03-12 | KAKKIS EMIL D President & CEO | Option exercise | +83,167 | $3.01 | $250K | 587,967 |
| 2020-03-12 | KAKKIS EMIL D President & CEO | Option exercise | +66,533 | $3.01 | $200K | 654,500 |
| 2020-03-12 | KAKKIS EMIL D President & CEO | Option exercise · Warrant (Right to Buy) | −83,167 | 0 | ||
| 2020-03-12 | KAKKIS EMIL D President & CEO | Option exercise · Warrant (Right to Buy) | −66,533 | 0 | ||
| 2020-03-01 | Huizenga Theodore Alan SVP, Controller and PAO | Grant or award | +4,400 | 19,958 | ||
| 2020-03-01 | Huizenga Theodore Alan SVP, Controller and PAO | Grant or award · Stock Option (Right to Buy) | +13,280 | 13,280 | ||
| 2020-03-01 | Harris Erik EVP & Chief Commercial Officer | Grant or award | +7,800 | 22,109 | ||
| 2020-03-01 | Harris Erik EVP & Chief Commercial Officer | Grant or award | +3,287 | 25,396 | ||
| 2020-03-01 | Harris Erik EVP & Chief Commercial Officer | Shares withheld for taxes | −824 | $56.08 | $46K | 24,572 |
| 2020-03-01 | Harris Erik EVP & Chief Commercial Officer | Grant or award · Stock Option (Right to Buy) | +22,000 | 22,000 | ||
| 2020-03-01 | Parschauer Karah Herdman EVP and General Counsel | Grant or award | +7,800 | 26,884 | ||
| 2020-03-01 | Parschauer Karah Herdman EVP and General Counsel | Grant or award | +5,634 | 32,518 | ||
| 2020-03-01 | Parschauer Karah Herdman EVP and General Counsel | Shares withheld for taxes | −2,118 | $56.08 | $119K | 30,400 |
| 2020-03-01 | Parschauer Karah Herdman EVP and General Counsel | Grant or award · Stock Option (Right to Buy) | +22,000 | 22,000 | ||
| 2020-03-01 | KAKKIS EMIL D President & CEO | Grant or award | +17,000 | 492,914 | ||
| 2020-03-01 | KAKKIS EMIL D President & CEO | Grant or award | +18,782 | 511,696 |
Page 30 of 32 · 632 trades